27 results about "VEGF binding" patented technology

The invention relates to anti-drug neutralizing antibody analysis. In particular, the present application relates to methods for detecting neutralizing antibodies against a vascular endothelial growth factor (VEGF) binding moiety and a programmed cell death ligand-1 (PD-L1) binding moiety in a biological sample from an individual administered a bispecific antibody drug comprising the VEGF binding moiety.

The present disclosure relates to VEGF antagonists. VEGF antagonists disclosed herein comprise a VEGF binding domain and a multimerization domain. Certain VEGF antagonists disclosed herein comprise five or more dimers, each dimer comprising two polypeptides, each polypeptide comprising a VEGF binding domain and a multimerization domain comprising an IgG Fc domain and, optionally, an IgM tailpiece. The disclosure further provides pharmaceutical compositions comprising the VEGF antagonists and methods of use of the VEGF antagonists in therapy, e.g., for treating angiogenic eye disorders. Also disclosed are nucleic acids encoding the VEGF antagonists, recombinant cells that express the VEGF antagonists, and methods of producing the VEGF antagonists.

Provided are methods and compositions for treatment of angiogenic disorders using anti-VEGF agents. The anti-VEGF agents comprise VEGF binding domains and have the ability to bind vitreous. Provided are exemplary embodiments of Fc-IgG fusion proteins with VEGF binding domains with strong heparin-binding characteristics, strong inhibition of VEGF mitogenic activity, and improved pharmacokinetics, namely longer half-lives of the anti-VEGF agents and consequently less frequent dosing.

Provided is a composition comprising aflibercept and a variant thereof, wherein the variant is a truncation variant with a truncated VEGF binding portion of aflibercept, and wherein the content of the truncation variant is less than or equal to about 20% by mass percentage. Also provided is a pharmaceutical formulation comprising the composition, and a method for preparing the same. Further, provided are a method for detecting the variant and use of the variant in quality inspection or quality control of an aflibercept-containing product.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

The present disclosure relates to VEGF antagonists. VEGF antagonists disclosed herein comprise a VEGF binding domain and a multimerization domain. Certain VEGF antagonists disclosed herein comprise five or more dimers, each dimer comprising two polypeptides, each polypeptide comprising a VEGF binding domain and a multimerization domain comprising an IgG Fc domain and, optionally, an IgM tailpiece. The disclosure further provides pharmaceutical compositions comprising the VEGF antagonists and methods of use of the VEGF antagonists in therapy, e.g., for treating angiogenic eye disorders. Also disclosed are nucleic acids encoding the VEGF antagonists, recombinant cells that express the VEGF antagonists, and methods of producing the VEGF antagonists.

Provided is a composition comprising aflibercept and a variant thereof, wherein the variant is a truncation variant with a truncated VEGF binding portion of aflibercept, and wherein the content of the truncation variant is less than or equal to about 20% by mass percentage. Also provided is a pharmaceutical formulation comprising the composition. Further, provided are a method for detecting the variant and use of the variant in quality inspection or quality control of an aflibercept-containing product.

The present invention provides a novel anti-Tie2 antibody or fragment thereof, and a bispecific antibody comprising the antibody and a VEGF-specific binding site. The anti-Tie2 antibody according to the present invention induced phosphorylation by specifically binding to the Tie2 protein. At this time, the antigen specificity and affinity of the anti-Tie2 antibody were excellent compared to existing ligands (Ang-1, Ang-2). In addition, the bispecific antibody comprising the anti-Tie2 antibody and the VEGF binding site inhibited VEGF while activating the Tie2 protein. In particular, the bispecific antibody effectively inhibited side effects that can be caused by an inhibitor of VEGF. In addition, the anti-Tie2 antibody or bispecific antibody exhibited a therapeutic effect on diseases in a mouse model of vascular abnormality-related diseases. Thus, the anti-Tie2 antibody and the bispecific antibody comprising the anti-Tie2 antibody and the VEGF-specific binding site according to the present invention can be used as a therapeutic agent for vascular abnormality-related diseases.

The present invention relates to VEGF binding agents, DLL4 binding agents, dual specific VEGF / DLL4 binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4 and dual specific antibodies that specifically bind human VEGF and / or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effective amount of an agent or antibody of the present invention to a patient having a tumor or cancer.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

The application belongs to the technical field of biological medicine, and particularly relates to a bispecific antibody against IL-8 and VEGF and application thereof. The bispecific antibody comprises a first antigen binding region and a second antigen binding region, wherein the first antigen binding region has IL-8 binding activity; and the second antigen binding region has VEGF binding activity. The application adopts a DVD-Ig mode design, connects variable regions of an anti-VEGF antibody and an anti-IL-8 antibody through a connecting peptide, and forms a novel bispecific antibody. The bispecific antibody can significantly block the biological activity of IL-8 and VEGF, and shows a tumor inhibition effect better than that of an anti-VEGF antibody or an anti-IL-8 antibody alone in a mouse glioma model. The application provides a new drug candidate molecule with higher efficiency and higher potential for cancer treatment.

The present disclosure relates to VEGF antagonists. VEGF antagonists disclosed herein comprise a VEGF binding domain and a multimerization domain. Certain VEGF antagonists disclosed herein comprise five or more dimers, each dimer comprising two polypeptides, each polypeptide comprising a VEGF binding domain and a multimerization domain comprising an IgG Fc domain and, optionally, an IgM tailpiece. The disclosure further provides pharmaceutical compositions comprising the VEGF antagonists and methods of use of the VEGF antagonists in therapy, e.g., for treating angiogenic eye disorders. Also disclosed are nucleic acids encoding the VEGF antagonists, recombinant cells that express the VEGF antagonists, and methods of producing the VEGF antagonists.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

Provided is a composition, which contains: i) a CTLA-4 antibody or an antigen-binding portion thereof capable of specifically binding to CLTA-4 and having an FcR-binding affinity, and ii) a recombinant fusion protein, wherein the recombinant fusion protein contains a PD-L1 antibody or an antigen-binding portion thereof capable of specifically binding to PD-L1 and having an FcR binding affinity, and a VEGF binding peptide, wherein the VEGF binding peptide is linked to the N-terminus of the heavy chain or light chain of the PD-L1 antibody or antigen-binding portion thereof. Further provided is the use of the composition in the preparation of a drug for treating tumors.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

A modified immune cell, characterized in that the modified immune cell can secrete two binding molecules, wherein the first binding molecule is a VEGF binding molecule or a VEGFR binding molecule, and the second binding molecule is a PDL1 binding molecule or a PD-1 binding molecule. The immune cell can quickly infiltrate a tumor microenvironment, proliferate rapidly and release a large number of cytokines, and thus has a good anti-tumor effect.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

The invention relates to fusion molecules targeting VEGF and angiopoietin and uses thereof. The present invention also relates to a polypeptide comprising two or three VEGF binding domains; and domains that bind to angiopoietin, as well as gene therapies for delivery of these polypeptides.

This application is directed to, in part, T cells and CAR-T cells expressing VEGF binding proteins or comprising VEGF gene knockouts, and methods of use thereof in treating cancer.

Provided is a composition comprising aflibercept and a variant thereof, wherein the variant is a truncation variant with a truncated VEGF binding portion of aflibercept, and wherein the content of the truncation variant is less than or equal to about 20% by mass percentage. Also provided is a pharmaceutical formulation comprising the composition, and a method for preparing the same. Further, provided are a method for detecting the variant and use of the variant in quality inspection or quality control of an aflibercept-containing product.

Disclosed herein are bispecific antibodies containing an anti-VEGF binding region conjugated to an anti-PD-1 binding region and uses thereof for treating cancer.

The present application relates to anti-drug neutralizing antibody analysis. In particular, the present application relates to a method for detecting neutralizing antibodies against a vascular endothelial growth factor (VEGF) binding moiety in a biological sample from an individual administered a bispecific antibody drug comprising the VEGF binding moiety and a programmed cell death ligand-1 (PD-L1) binding moiety.